Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma

Melanoma Research
Ashlyn R SeeleyRobert M Conry

Abstract

Approximately half of melanomas are driven by a point mutation in the BRAF kinase gene, targetable with vemurafenib. However, the chief limitation of continuous BRAF inhibition is that the majority of patients develop resistance within 8 months, including those with surgically unresectable stage III melanoma. Researchers retrospectively reviewed medical records of all patients at our institution with surgically incurable BRAF V600E mutated stage III or limited stage IV melanoma treated with induction vemurafenib, stopped electively during ongoing response, followed by consolidative radiation therapy with or without intervening surgery to debulk nodal metastases. In our six-patient cohort, the median duration of vemurafenib was 5.8 months and the median radiation dose was 57 Gy using conventional fractionation. This algorithm produced 100% locoregional control at 29+ months following radiation and a median progression-free survival of 32.5+ months. Three of six patients remained progression free, and three relapsed in a single organ and achieved ongoing complete response to subsequent therapy. Outcomes greatly exceeding those reported with either BRAF inhibition or radiation alone suggest unanticipated synergies with this therap...Continue Reading

References

Oct 1, 1975·The British Journal of Radiology·D P Kingsley
Feb 18, 2004·International Journal of Radiation Oncology, Biology, Physics·Sandra DemariaSilvia C Formenti
Jan 11, 2007·The Journal of Experimental Medicine·Bin ZhangHans Schreiber
Jul 4, 2008·Cancer Control : Journal of the Moffitt Cancer Center·Mark I GimbelJonathan S Zager
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Sep 8, 2010·The New England Journal of Medicine·Keiran S M Smalley, Vernon K Sondak
Feb 8, 2011·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Maria J SambadeJaniel M Shields
Feb 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Georgina V LongRichard F Kefford
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Jun 7, 2011·The New England Journal of Medicine·Caroline RobertJedd D Wolchok
Jun 10, 2011·The Journal of Investigative Dermatology·Mizuho Fukunaga-KalabisMeenhard Herlyn
Mar 9, 2012·The New England Journal of Medicine·Michael A PostowJedd D Wolchok
Jun 6, 2012·The New England Journal of Medicine·Keith T FlahertyUNKNOWN METRIC Study Group
Sep 4, 2012·Journal of the American Academy of Dermatology·Kevin P BoydLauren C Hughey
Nov 14, 2012·Nuclear Medicine and Biology·Thomas JandlEkaterina Dadachova
Dec 4, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chengwen LiuPatrick Hwu
Mar 20, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Oliver KleinRichard F Kefford
Apr 5, 2013·The New England Journal of Medicine·Antoni RibasJedd Wolchok
Apr 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karlijn KoersJos A van der Hage
May 24, 2013·JAMA Dermatology·Lise BoussemartCaroline Robert
Aug 7, 2013·Cancer Cell International·Rüdiger M ZimmererFrank Tavassol
Nov 7, 2013·European Journal of Dermatology : EJD·Lucie PeuvrelBrigitte Dreno
Nov 7, 2013·Frontiers in Immunology·Patrick A Ott, Nina Bhardwaj
Dec 4, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Reinhard DummerJeannine D Rinderknecht
Jun 25, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Siwen Hu-LieskovanAntoni Ribas
Jul 6, 2014·Melanoma Research·Marco RastrelliCarlo R Rossi
Sep 30, 2014·The New England Journal of Medicine·James LarkinAntoni Ribas
Oct 17, 2014·Cancer Research·Kristel KemperRenée van Amerongen

❮ Previous
Next ❯

Citations

May 18, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ryan RobbTerence M Williams

❮ Previous
Next ❯

Methods Mentioned

BETA
dissection
surgical resection

Software Mentioned

SPSS

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

Related Papers

The New England Journal of Medicine
Taegyun KimMin-Geol Lee
The New England Journal of Medicine
David B Solit, Neal Rosen
International Journal of Radiation Oncology, Biology, Physics
Joseph C HodgesChristopher H Crane
International Journal of Radiation Oncology, Biology, Physics
A PollackJ B Putnam
© 2022 Meta ULC. All rights reserved